AbbVie Inc. $ABBV Stock: Sanders Morris Harris LLC Raises Holdings

Sanders Morris Harris LLC lifted its stake in AbbVie Inc. (NYSE:ABBV) by 972.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,463 shares of the company’s stock after buying an additional 18,555 shares during the period. Sanders Morris Harris LLC’s holdings in AbbVie were worth $5,358,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ABBV. Ranch Capital Advisors Inc. increased its position in AbbVie by 37.0% during the 1st quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company’s stock worth $3,238,000 after purchasing an additional 4,017 shares in the last quarter. Capital Advisors Inc. OK lifted its position in AbbVie by 11.2% during the second quarter. Capital Advisors Inc. OK now owns 447,129 shares of the company’s stock valued at $112,516,000 after buying an additional 45,132 shares in the last quarter. Danica Pension Livsforsikringsaktieselskab purchased a new stake in AbbVie during the second quarter worth approximately $23,557,000. Wedge Capital Management L L P NC raised its stake in shares of AbbVie by 7.5% in the 2nd quarter. Wedge Capital Management L L P NC now owns 134,579 shares of the company’s stock valued at $33,865,000 after acquiring an additional 9,380 shares during the period. Finally, Mission Wealth Management LP boosted its position in AbbVie by 119.1% during the 2nd quarter. Mission Wealth Management LP now owns 69,052 shares of the company’s stock worth $17,376,000 after purchasing an additional 37,531 shares during the period. 70.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ABBV has been the topic of a number of recent analyst reports. UBS Group boosted their price objective on shares of AbbVie from $260.00 to $275.00 and gave the stock a “neutral” rating in a report on Tuesday, October 6th. Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 5th. BNP Paribas Exane boosted their target price on shares of AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a research note on Tuesday, August 11th. HSBC lifted their price target on shares of AbbVie from $300.00 to $315.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Finally, Canaccord Genuity Group boosted their price objective on AbbVie from $282.00 to $290.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $277.18.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: New Phase 3 AFFIRM data showed that subcutaneous SKYRIZI improved clinical and endoscopic outcomes versus placebo in adults with moderately to severely active Crohn’s disease, with safety consistent with its established profile. The results could support regulatory review of a more convenient induction option and strengthen AbbVie’s post-Humira immunology growth story. Did SKYRIZI’s Subcutaneous Crohn’s Data Just Shift AbbVie’s Immunology Investment Narrative?
• Positive Sentiment: Analysts remain constructive ahead of earnings. RBC reaffirmed an “outperform” rating and cited potential third-quarter top-line strength from RINVOQ, SKYRIZI and Vraylar, while Erste Group raised its 2027 EPS forecast to $16.34 from $16.19 and maintained a Buy rating. AbbVie Poised for Q3 Top-Line Beat
• Positive Sentiment: AbbVie benefited from a wider healthcare-sector rally, while unusually heavy call-option activity—86,296 calls purchased versus typical volume of 15,836—suggested increased short-term bullish positioning.
• Neutral Sentiment: Some investors and analysts are comparing AbbVie unfavorably with Sanofi, whose upgraded 2026 outlook, Dupixent growth and lower valuation may offer a more attractive risk-reward profile. This is a relative-investment consideration rather than a direct change to AbbVie’s fundamentals. Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?
• Negative Sentiment: RBC’s $280 price target is below the recently quoted trading level, indicating limited near-term upside at that target. A recent executive stock sale may also weigh modestly on sentiment, although it does not alter the company’s operating outlook.

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. This trade represents a 30.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.06% of the stock is currently owned by corporate insiders.

AbbVie Stock Up 3.4%

NYSE:ABBV traded up $9.22 during trading hours on Wednesday, reaching $283.58. 5,620,782 shares of the company’s stock were exchanged, compared to its average volume of 6,410,426. The company has a market capitalization of $501.03 billion, a P/E ratio of 80.11, a price-to-earnings-growth ratio of 1.28 and a beta of 0.24. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $285.40. The business’s 50-day simple moving average is $260.41 and its two-hundred day simple moving average is $237.87.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. The company had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business’s quarterly revenue was up 10.2% on a year-over-year basis. During the same period in the prior year, the firm earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, sell-side analysts anticipate that AbbVie Inc. will post 13.95 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 2.4%. The ex-dividend date is Thursday, October 15th. AbbVie’s payout ratio is 195.48%.

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.